The U.K.-based consultancy firm Assero and the European CRO S-Cubed have joined forces to establish A3 Informatics, a joint venture that is designed to help companies working with CDISC (Clinical Data Interchange Standards Consortium) standards and assist with data management. The plan is to showcase the business at the PhUSE Annual Conference in Edinburgh, Scotland on October 8, 2017.
“I am proud to be bringing a set of technologies to the industry that it has long needed,” noted Dave Iberson-Hurst, who has advocated the use of standards for the last 15 years and has helped design and develop A3 Informatics’ “Tools: The Glandon Suite.” “I am looking forward to introducing A3 Informatics to the wider community and changing the way that we work with data.”
Iberson-Hurst has worked with S-Cubed’s managing director Scott McGregor and partner Niels Both for more than a decade. S-cubed is a European company based in Denmark and the U.K. with full-service CRO capabilities, specializing in biometrics, CDISC standards (implementation and conversion), regulatory affairs, business intelligence, quality assurance, and project management.
Both’s experience of working with CDISC standards and awareness of the issues that companies faced with implementation will be vital for A3 Informatics, according to a joint statement from both companies.
“Dave and I have worked together for many years and it is clear that there has to be another way of working with the data in clinical trials,” he said. “A3 Informatics offers solutions that can drive the industry away from endless mapping and conversions and lead to a more efficient and accurate way of working.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.